tirzepatide and liver disease damage Eli Lilly released some preliminary results using Tirzepatide to treat fatty liver (MASH) @sashahighmd #mash #nash #liverhealth #joinfridays #zepbound Eli Lilly touts tirzepatide's midstage

Its so easy

In a randomized, phase 3, open-label trial comparing two oral GLP-1 receptor agonists, a greater percentage of adults receiving orforglipron 12 mg or 36 mg (Eli Lilly) were able to achieve an HbA1c of less than 7%, 6.5% and 5.7% vs

Analyst projections indicate substantial revenue generation for Zepbound over the next decade, driven by increasing diagnosis rates of obesity and the drug's demonstrated efficacy in clinical trials

If you notice these less common effects, discuss them with your doctor

In the real world, the number is lower due to internal resistance of the pack and the fact the voltage will decay as the battery drains

Patients should discuss contraceptive options with their primary care or gynecology provider, as some methods may be preferable depending on individual health factors